were identified. Logistic regression models tested the effect of BNS on continence and surgical margin rates. Cox regression models tested the effect of BNS on BCR.
INTRODUCTION AND OBJECTIVES: Localized low-risk prostate cancer (PCa) can have different biological behaviour and its treatment remains controversial. We investigated the incidence of unfavorable features (defined as ISUP Grade ! 3 and/or stage ! pT3a) after radical prostatectomy (RP), in patients initially diagnosed with microfocal PCa (miPCa) at prostate biopsy (PBx) .
METHODS: The current multicenter study included patients diagnosed with miPCa at PBx and having undergone RP. miPCa was defined as a single positive focus 3 mm. Patients were stratified according to the D'Amico risk classification and surgical approach (retropubic, laparoscopic, and robot assisted RP).
RESULTS: Overall 647 patients were included: 461, 139 and 47 patients were classified as low-, intermediate-and high-risk according to the D'Amico risk classification, respectively. Mean age was 65.7 years. Mean PSA was 8.25 ng/ml and PSAD was 0.18. Overall 242 (37.4%) patients were upgraded after RP. Unfavorable characteristics were found in 172 (26.6%), 91 (52.9%) of which were previously classified as low-risk patients. 159 (34.5%) low-risk patients were upgraded after RP: an ISUP Grade ! 3 PCa was diagnosed in the 32.7% of them (42, 5 and 5 patients with ISUP Grade 3, 4 and 5 respectively). Moreover 113 (17.5%) patients had an extraprostatic extension of the cancer (pathological stage ! pT3a) and 119 (19.2%) had positive surgical margins. Overall 360 (55.6%), 203 (31.4%) and 84 (13.0%) patients had undergone retropubic, laparoscopic and robot assisted RP. Interestingly, no significant differences were reported in positive surgical margins incidence according to the surgical approach (p [ 0.116), despite the different usage of the nerve sparing technique (35.6, 44.3 and 67.8% in retropubic, laparoscopic and robot assisted RP, respectively). It is also notable that 1 (0.2%) patient, previously diagnosed with a GS 6 PCa, was definitively classified as pT0 after RP. The ROC curve analysis demonstrated that PSA, PSAD, and D'Amico risk classification had an AUC value of 0.628, 0.681, and 0.631 respectively to predict the risk of unfavorable features. The PSAD had the best predictive ability, significantly higher than PSA METHODS: 9,742 patients who underwent RP between 2000 and 2017 with or without PLND were identified in a multi-institutional database of four centers. Only patients with more than 5% risk of lymph node invasion according to the Briganti nomogram were included. Univariable and multivariable Cox regression models tested the effect of extended PLND on biochemical recurrence (BCR), clinical recurrence (CR) and cancer-specific mortality (CSM). All analyses were repeated after propensity score matching. Matching was performed for pathologic primary Gleason, pathologic tumor stage, prostate specific antigen (PSA) and surgical margin.
RESULTS: Overall, 707 (7.3%) patients did not undergo PLND. Of those, 520 vs. 187 harbored D'Amico high-or intermediate-risk characteristics, respectively. Individuals without PLND had significantly lower median PSA and more frequently harbored biopsy Gleason score 6 as well as pathologic T2 stage. The median number of removed lymph nodes was 14 in the PLND cohort; 17. 6% (n[1,714) of the patients with PLND harbored lymph node metastases. BCR-free rates were 64.2% vs. 50.5%, CR-free rates were 90.1 vs. 73.8% and CSM-free rates were 96.5 vs. 93.1%, at 120 months after RP for no PLND vs. PLND, respectively. After adjustment for pathologic covariables, PLND did not achieve independent predictor status for BCR, CR and CSM (all p>0.05). After 2:1 propensity score matching, BCR-free rates were 62.1 vs. 63.9%, CR-free rates were 88.8 vs. 90.0% and CSM-free rates were 96.9 vs. 96.4% at 120 months after RP for PLND and no PLND, respectively. Multivariable Cox regression models after matching revealed that PLND is no independent predictor for BCR, CR and CSM (all p!0.5).
CONCLUSIONS: Patients with D'Amico high-or intermediaterisk prostate cancer without PLND at radical prostatectomy did not show worse oncologic outcome compared to patients who underwent PLND. While PLND is the most accurate staging procedure, its therapeutic value remains unclear.
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